Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleksi Petrenko

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Cell Cycle (Georgetown, Tex.)|March 21, 2013
Direct reprogramming en route to neoplastic transformationAlice Nemajerova, Oleksi Petrenko
Molecular Cancer Research : MCR|January 7, 2004
The MDM2-p53 interactionUte M Moll, Oleksi Petrenko
Molecular Cell|January 25, 2005
Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathwayOleksi Petrenko, Ute M Moll
Cell Division|July 21, 2007
MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse modelsGünter Fingerle-Rowson, Oleksi Petrenko
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreasIrene Ischenko, Oleksi Petrenko, Michael J Hayman
Oncotarget|July 10, 2015
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cellsIrene Ischenko, Oleksi Petrenko, Michael J Hayman
Molecular and Cellular Biology|August 5, 2003
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivoOleksi Petrenko, Alexander Zaika, Ute M Moll
Iscience|February 3, 2025
Intratumor heterogeneity in KRAS signaling shapes treatment resistanceOleksi Petrenko, Varvara Kirillov, Stephen D'Amico, et al.
Cancer Research|January 15, 2025
Editor's Note: Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivoFlaminia Talos, Oleksi Petrenko, Patricio Mena, et al.
Biorxiv : the Preprint Server for Biology|September 21, 2023
STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancerStephen D'Amico, Varvara Kirillov, Oleksi Petrenko, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Cell Cycle (Georgetown, Tex.)|March 21, 2013
Direct reprogramming en route to neoplastic transformationAlice Nemajerova, Oleksi Petrenko
Molecular Cancer Research : MCR|January 7, 2004
The MDM2-p53 interactionUte M Moll, Oleksi Petrenko
Molecular Cell|January 25, 2005
Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathwayOleksi Petrenko, Ute M Moll
Cell Division|July 21, 2007
MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse modelsGünter Fingerle-Rowson, Oleksi Petrenko
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreasIrene Ischenko, Oleksi Petrenko, Michael J Hayman
Oncotarget|July 10, 2015
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cellsIrene Ischenko, Oleksi Petrenko, Michael J Hayman
Molecular and Cellular Biology|August 5, 2003
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivoOleksi Petrenko, Alexander Zaika, Ute M Moll
Iscience|February 3, 2025
Intratumor heterogeneity in KRAS signaling shapes treatment resistanceOleksi Petrenko, Varvara Kirillov, Stephen D'Amico, et al.
Cancer Research|January 15, 2025
Editor's Note: Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivoFlaminia Talos, Oleksi Petrenko, Patricio Mena, et al.
Biorxiv : the Preprint Server for Biology|September 21, 2023
STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancerStephen D'Amico, Varvara Kirillov, Oleksi Petrenko, et al.
Pageof 4